The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed the day trading at $9.37 down -1.37% from the previous closing price of $9.50. In other words, the price has decreased by -$1.37 from its previous closing price. On the day, 1.71 million shares were traded.
Ratios:
For a better understanding of AVDL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.33 and its Current Ratio is at 2.73. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On June 12, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $27.
Oppenheimer reiterated its Outperform rating for the stock on March 05, 2024, while the target price for the stock was revised from $27 to $29.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 12.22.
Stock Price History:
Over the past 52 weeks, AVDL has reached a high of $17.30, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 6.16%, while the 200-Day Moving Average is calculated to be -8.75%.
Shares Statistics:
A total of 96.63M shares are outstanding, with a floating share count of 88.37M. Insiders hold about 8.65% of the company’s shares, while institutions hold 77.13% stake in the company.
Earnings Estimates
A detailed examination of Avadel Pharmaceuticals plc (AVDL) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.39 and $0.09 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.72, with 4.0 analysts recommending between $1.24 and $0.46.
Revenue Estimates
7 analysts predict $61.46M in revenue for the current quarter. It ranges from a high estimate of $63.8M to a low estimate of $59M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $41.5MFor the next quarter, 7 analysts are estimating revenue of $70.61M. There is a high estimate of $72.4M for the next quarter, whereas the lowest estimate is $69.1M.
A total of 7 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $261.5M, while the lowest revenue estimate was $257.54M, resulting in an average revenue estimate of $260.08M. In the same quarter a year ago, actual revenue was $169.12MBased on 7 analysts’ estimates, the company’s revenue will be $339.28M in the next fiscal year. The high estimate is $356.5M and the low estimate is $321.2M.
